Abstract: The present invention relates to amino acid sequences binding to serum albumin. In particular, the present invention relates to improved immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”), and more in particular improved heavy-chain immunoglobulin single variable domains, binding to serum albumin, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such improved serum albumin binders.
Abstract: The present invention relates to improved immunogenicity assays and methods for performing the same. In particular, the present invention relates to improved immunogenicity assays that are capable of distinguishing neutralizing anti-drug antibodies from non-neutralizing anti-drug antibodies. More in particular, the present invention relates to improved immunogenicity assays that allow (amounts and/or concentrations of) neutralizing anti-drug antibodies to be detected and/or measured in a sample even in the presence of non-neutralizing anti-drug antibodies.
Type:
Application
Filed:
March 29, 2018
Publication date:
March 31, 2022
Applicant:
Ablynx N.V.
Inventors:
Annelies Coddens, Veerle Snoeck, Marie-Ange Buyse, Carlo Boutton
Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.
Type:
Application
Filed:
June 4, 2018
Publication date:
March 24, 2022
Applicants:
Ablynx N.V., Merck Patent GmbH
Inventors:
Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
Type:
Application
Filed:
October 15, 2021
Publication date:
March 3, 2022
Applicants:
Ablynx N.V., Sanofi
Inventors:
Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
Abstract: The present invention relates to immunoglobulins that specifically bind CD40L and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of CD40L and are safe.
Type:
Grant
Filed:
November 28, 2016
Date of Patent:
February 15, 2022
Assignee:
Ablynx N.V.
Inventors:
Els Pattyn, Ariëlla Van de Sompel, Peter Meerts, Marie-Ange Buyse, Maarten Dewilde, Gerald Beste, Jaromir Vlach, Jonathan Hsu
Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
Type:
Application
Filed:
August 23, 2021
Publication date:
December 30, 2021
Applicant:
Ablynx N.V.
Inventors:
Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.
Type:
Grant
Filed:
March 22, 2021
Date of Patent:
December 28, 2021
Assignees:
Ablynx N.V., Sanofi
Inventors:
Heidi Rommelaere, Ann Brigé, Sigrid Cornelis, Bruno Dombrecht, Eric Lorent, Melanie Rieger, Timothy Soos, John Park, Bernd Weigle, Klaus Erb
Abstract: T cell recruiting polypeptides are provided that bind the constant domain of TCR on a T cell. The polypeptides can be used in methods for treatment of cancers.
Type:
Application
Filed:
December 21, 2020
Publication date:
December 23, 2021
Applicant:
Ablynx N.V.
Inventors:
Annelies Roobrouck, Diane Van Hoorick, João Vieira
Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
Type:
Application
Filed:
August 23, 2021
Publication date:
December 16, 2021
Applicant:
Ablynx N.V.
Inventors:
Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
Type:
Application
Filed:
August 23, 2021
Publication date:
December 16, 2021
Applicant:
Ablynx N.V.
Inventors:
Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Néotère Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference and/or give rise to an (aspecific) signal in such an assay (such as in an ADA immunoassay; methods for modifying and/or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er)/reduced tendency to give rise to such protein interference or such a signal; modified and/or improved ISV's that have no or a low(er)/reduced tendency to give rise to such protein interference or such a signal.
Type:
Grant
Filed:
June 6, 2017
Date of Patent:
December 7, 2021
Assignee:
Ablynx N.V.
Inventors:
Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: —assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
Type:
Grant
Filed:
June 6, 2017
Date of Patent:
December 7, 2021
Assignee:
Ablynx N.V.
Inventors:
Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
Abstract: The present invention relates method for purifying antibodies, said method comprising a limited number of steps while still allowing obtaining high yields of purified antibodies with an appropriate degree of purity. Briefly, this method comprises only filtration and precipitation steps, omitting the need for chromatography steps.
Type:
Application
Filed:
October 8, 2019
Publication date:
December 2, 2021
Applicant:
Ablynx N.V.
Inventors:
Peter Casteels, Willem Van De Velde, Anthony Van De Putte, Sindi De Vrieze
Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.
Type:
Application
Filed:
April 19, 2021
Publication date:
November 11, 2021
Applicant:
Ablynx N.V.
Inventors:
Erik Depla, Mauro Sergi, Peter Casteels
Abstract: Described herein are methods, assays and techniques for detecting and/or measuring anti-drug antibodies that bind to a protein, polypeptide or other compound or molecule that comprises at least one immunoglobulin variable domain with an exposed C-terminal region.
Abstract: The present invention relates to immunoglobulins that specifically bind Kv1.3 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Kv1.3.
Type:
Grant
Filed:
June 18, 2015
Date of Patent:
October 19, 2021
Assignee:
Ablynx N.V.
Inventors:
Diane Van Hoorick, Erik Depla, Frank Kamiel Delphina Verdonck, Veerle Delanote, Daniel Janssen, Francis Descamps, Mark Edward Labadia, Ann Mikhail, Alisa K. Waterman
Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
Type:
Grant
Filed:
October 2, 2018
Date of Patent:
October 19, 2021
Assignee:
Ablynx N.V.
Inventors:
Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria-Laura Sargentini-Maier, Özkan Yalkinoglu
Abstract: The present invention relates to amino acid sequences binding to serum albumin. In particular, the present invention relates to improved immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVD's”), and more in particular improved heavy-chain immunoglobulin single variable domains, binding to serum albumin, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such improved serum albumin binders.